Medical devices industry private equity deals in Q3 2019 total $406.31m globally

27 November 2019 (Last Updated November 27th, 2019 07:06)

Medical devices industry private equity deals in Q3 2019 total $406.31m globally

Total medical devices industry private equity deals in Q3 2019 worth $406.31m were announced globally, according to GlobalData’s deals database.

  • Embed this chart

    Embed this chart into your website

    Copy and paste the code below into your website to display the chart.

The value marked an increase of 47.3% over the previous quarter and a drop of 67.5% when compared with the last four-quarter average, which stood at $1.25bn.

Comparing deals value in different regions of the globe, North America held the top position, with total announced deals in the period worth $329.1m. At the country level, the US topped the list in terms of deal value at $329.1m.

In terms of volume, Europe emerged as the top region for medical devices industry private equity deals globally, followed by North America and then Asia-Pacific.

The top country in terms of private equity deals activity in Q3 2019 was the US with ten deals, followed by Germany with four and France with two.

In 2019, as of the end of Q3 2019, medical devices private equity deals worth $2.2bn were announced globally, marking a decrease of 76.7% year on year.

Medical devices industry private equity deals in Q3 2019: Top deals

The top five medical devices industry private equity deals accounted for 86.7% of the overall value during Q3 2019.

The combined value of the top five medical devices private equity deals stood at $352.45m, against the overall value of $406.31m recorded for the month.

The top five medical devices industry deals of Q3 2019 tracked by GlobalData were:

1) Audax Private Equity’s $170m private equity deal with Aspen Surgical Products

2) The $69.45m private equity deal with Translumina Therapeutics by Everstone Capital AdvisorsLtd

3) Perceptive Advisors’ $56m private equity deal with AgaMatrix and WaveForm Technologies

4) The $30m private equity deal with Skincure Oncology by Seacoast Capital Managers

5) Ampersand Capital Partners’ private equity deal with Interpace Diagnostics Group for $27m.

Verdict deals analysis methodology

This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.

GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.

More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.